Engene announces the election of paul hastings and wouter joustra to its board of directors

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced the election of paul hastings and wouter joustra as new members of its board of directors at the company's 2024 annual meeting of shareholders. shareholders also reelected incumbent director lota zoth. each will serv.
ENGN Ratings Summary
ENGN Quant Ranking